p-Methoxycarbonylmethylphenylacetyl bromide | 84325-98-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-Methoxycarbonylmethylphenylacetyl bromide
• 英文别名: Methyl 4-(α-bromo-acetyl)-phenylacetate；Methyl [4-(bromoacetyl)phenyl]acetate；methyl 2-[4-(2-bromoacetyl)phenyl]acetate
• CAS: 84325-98-4
• 化学式: C₁₁H₁₁BrO₃
• 分子量: 271.111
• InChiKey: CJUICSXDEFZPCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  p-Methoxycarbonylmethylphenylacetyl bromide 在 溶剂黄146 selenium(IV) oxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 methyl 2-[4-(6-nitro-2-oxo-1,4-benzoxazin-3-yl)phenyl]acetate
  参考文献：
  名称：

  Shridhar, D. R.; Sastry, C. V. Reddy; Lal, B., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1982, vol. 21, # 6, p. 602 - 604

  摘要：

  DOI：
• 作为产物：
  描述：

  (4-乙酰基苯基)乙酸甲酯 在 溴 作用下， 以 四氯化碳 为溶剂， 反应 1.0h， 以85%的产率得到p-Methoxycarbonylmethylphenylacetyl bromide
  参考文献：
  名称：

  Shridhar, D. R.; Sastry, C. V. Reddy; Lal, B., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1982, vol. 21, # 6, p. 602 - 604

  摘要：

  DOI：

文献信息

• [EN] PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINONE ET DE PYRIMIDINONE COMME INHIBITEURS DU FACTEUR XIA
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2013093484A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，它们的盐和N-氧化物，以及它们的溶剂合物和前药（其中字符如描述中所定义）。一般式(I)的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓栓塞疾病方面是有用的。
• Piperazine derivatives, medicaments comprising these compounds, their
  申请人：Dr. Karl Thomae GmbH

  公开号：US05922717A1

  公开（公告）日：1999-07-13

  The present invention relates to piperazine derivatives of the general formula ##STR1## in which R.sub.a, Y.sub.1 to Y.sub.3 and E are defined herein, tautomers thereof, stereoisomers thereof, including their mixtures, and salts thereof, and in particular physiologically tolerated salts thereof with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, such as aggregation-inhibiting activity. This invention also relates to medicaments comprising these compounds and to processes for the preparation of these compounds.

  本发明涉及一般式##STR1##的哌嗪衍生物，其中R.sub.a，Y.sub.1至Y.sub.3和E在此定义，其互变异构体，立体异构体，包括它们的混合物，以及其盐，特别是与无机或有机酸或碱的生理耐受盐。这些化合物具有有价值的药理特性，如抑制聚集活性。本发明还涉及包含这些化合物的药物和制备这些化合物的方法。
• Piperazine derivatives, pharmaceutical compositions containing these
  申请人：Karl Thomae, GmbH

  公开号：US05700801A1

  公开（公告）日：1997-12-23

  Piperazine derivatives useful in the treatment or prevention of inflammation, bone degradation, thrombosis and tumor metastasis. Exemplary species are: (a) \x9b4-trans-\x9b3-\x9b4-(4-Pyridyl)-piperazin-1-yl!propionyl!amino!-cyclohexanecarb oxylic acid, (b) 3-\x9b4-trans-\x9b4-(4-Pyridyl)-piperazin-1-yl!carbonylamino!-cyclohexylpropioni c acid, (c) 3-\x9b4-trans-\x9b4-(4-Pyridyl)-piperazin-1-yl!malonylamino!cyclohexylcarboxylic acid, (d) Methyl \x9b4-trans-\x9b3-\x9b4-(4-pyridyl)-piperazin-1-yl!-propionyl!-amino!cyclohexane carboxylate, (e) Methyl 3-\x9b4-trans-\x9b4-(4-pyridyl)-piperazin-1-yl!-carbonylamino!cyclohexyl propionate, (f) Methyl \x9b4-trans-\x9b4-(4-pyridyl)-piperazin-1-yl!-malonylamino!-cyclohexyl carboxylate, (g) Cyclohexyl \x9b4-trans-\x9b\x9b4-(4-pyridyl)-piperazin-1-yl!-acetyl!-amino!-cyclohexane carboxylate, and (h) Isobutyl \x9b4-trans-\x9b\x9b4-(4-pyridyl)-piperazin-1-yl!-acetyl!-amino!-cyclohexane carboxylate.

  哌嗪衍生物可用于治疗或预防炎症、骨质破坏、血栓形成和肿瘤转移。其中一些种类包括：(a) \x9b4-顺- \x9b3-\x9b4-(4-吡啶基)-哌嗪-1-基!丙酰基!氨基!-环己烷羧酸，(b) 3-\x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!羰基氨基!-环己基丙酸，(c) 3-\x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!马来酰氨基!环己基羧酸，(d) 甲基 \x9b4-顺- \x9b3-\x9b4-(4-吡啶基)-哌嗪-1-基!-丙酰基!-氨基!环己烷羧酸甲酯，(e) 甲基 3-\x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!-羰基氨基!环己基丙酸甲酯，(f) 甲基 \x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!-马来酰氨基!-环己基羧酸甲酯，(g) 环己基 \x9b4-顺-\x9b\x9b4-(4-吡啶基)-哌嗪-1-基!-乙酰基!-氨基!环己烷羧酸酯，以及(h) 异丁基\x9b4-顺-\x9b\x9b4-(4-吡啶基)-哌嗪-1-基!-乙酰基!-氨基!环己烷羧酸酯。
• COMPOUNDS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150152112A1

  公开（公告）日：2015-06-04

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式（I）的化合物，它们的盐和N-氧化物，以及它们的溶剂化物和前药（其中字符如描述中所定义）。一般式（I）的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓性疾病方面非常有用。
• Pyrimidinone and its derivatives inhibiting factor XIa
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10717738B2

  公开（公告）日：2020-07-21

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供通式(I)化合物、其盐类和N-氧化物，以及其溶解物和原药（其中特征如描述中所定义）。通式（I）化合物是因子 XIa 的抑制剂，因此可用于预防和/或治疗血栓栓塞性疾病。